Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.
D000671:Amputation, Surgical; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005266:Femoral Neoplasms / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D002955:Leucovorin / Q000008:administration & dosage* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000517:prevention & control; D008727:Methotrexate / Q000008:administration & dosage* / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D014750:Vincristine; D002955:Leucovorin; D008727:Methotrexate